Toll-like receptors: Another player in the pathogenesis of the anti-phospholipid syndrome

Lupus

Volumn 17, Issue 10, 2008, Pages 937-942

  Raschi, E ^a   Borghi, M O ^a   Grossi, C ^a   Broggini, V ^a   Pierangeli, S ^b   Meroni, Pier Luigi ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Ospedale San Luca   (Italy)

Author keywords

Anti phospholipid syndrome; Beta2 glycoprotein I; Innate immunity; Thrombosis; Toll like receptors

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOMODULATING AGENT; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; RECEPTOR ANTIBODY; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7 ANTAGONIST; TOLL LIKE RECEPTOR 9 ANTAGONIST; TOLL LIKE RECEPTOR ANTIBODY; TOLL LIKERECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; BLOOD CLOT; CELL ACTIVATION; CELLULAR IMMUNITY; DISEASE COURSE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG SYNTHESIS; EFFECTOR CELL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; INNATE IMMUNITY; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOGENESIS; THROMBOSIS; AUTOIMMUNITY; FIBRINOLYSIS; GENETICS; PHYSIOLOGY;

ANTIGEN-ANTIBODY REACTIONS; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; FIBRINOLYSIS; HUMANS; IMMUNITY, INNATE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 58849090583     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308095140     Document Type: Review

References (52)

1. Holers VM Girardi G Mo L. et al. Complement C3 activation is required for anti-phospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211-220.
2. Girardi G Berman J Redecha P. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphosholipid syndrome. J Clin Invest 2003; 112: 1644-1654.
3. Girardi G Redecha P Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222-1226.
4. Berman J Girardi G Salmon J. TNF-α is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174: 485-490.
5. Redecha P Tilley R Tencati M. Tissue factor: A link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110: 2423-2431.
6. Fischetti F Durigotto P Pellis V. et al. Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106: 2340-2346.
7. Pierangeli SS Girardi G Vega-Ostertag M Liu X Espinola RG Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52: 2120-2124.
8. Martinez de la Torre Y Buracchi C Borroni EM. et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci USA 2007; 104: 2319-2324.
9. Shoenfeld Y Blank M Cervera R Font J Raschi E Meroni PL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 2006; 65: 2-6.
10. Medhzitov R. Toll-like receptors and innate immunity. Nat Rev 2001; 1: 135-145.
11. Takeda K Kaisho T Akira S. Toll-like receptors. Ann Rev Immunol 2003; 21: 335-376.
12. Kanzler H Barrat FJ Hessel EM Coffman HR. Therapeutic targetting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552-559.
13. Marsland BJ Kopf M. Toll-like receptors: Paving the path to T cell-driven autoimmunity. Curr Opin Immunol 2007; 19: 611-614.
14. Marshak-Rothstein A Ohashi PS. Intricate connections between innate and adaptive autoimmunity. Curr Opin Immunol 2007; 19: 603-605.
15. Marshak-Rothstein A Rifkin IR. Immunologically active autoantigens: The role of Toll-like receptors in the development of chronic inflammatory disease. Ann Rev Immunol 2007; 25: 419-441.
16. Hurst J von Landenberg P. Toll-like receptors and autoimmunity. Autoimmun Rev 2008; 7: 204-208.
17. Chen K Huang J Gong W Iribarren P Dunlop NM Wang JM. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007; 7: 1271-1285.
18. Krieg AM Vollmer J. Toll-like receptors 7, 8, and 9: Linking innate immunity to autoimmunity. Immunol Rev 2007; 220: 251-269.
19. Urbanus RT Derksen RHMW de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospholipid syndrome. Blood Rev 2008; 22: 93-105.
20. Meroni PL. Pathogenesis of the antiphospholipid syndrome: An additional example of the mosaic of autoimmunity. J Autoimmun 2008; 30: 99-103.
21. Meroni PL Raschi E Ronda N Borghi MO. Humural immunity against endothelium: Theory or reality. Trends Immunol 2005; 26: 275-281.
22. Raschi E Testoni C Bosisio D. et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495-3500.
23. Sorice M Longo A Capozzi A. et al. Anti-β2glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56: 2687-2697.
24. Bouma B de Groot PG van den Elsen JM. et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-5174.
25. Del Papa N Sheng YH Raschi E. et al. Human β2glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-β2glycoprotein I antibodies. J Immunol 1998; 160: 5572-5578.
26. Meroni PL Tincani A Sepp N. et al. Endothelium and the brain in CNS lupus. Lupus 2003; 12: 1-10.
27. 2glycoprotein I to human endothelial cells is mediated by Annexin II. J Biol Chem 2000; 275: 15441-15448.
28. 2glycoprotein I antibodies. Blood 2005; 105: 1964-1969.
29. 2GPI) antibodies is mediated by Annexin II cross linking and may involve TLR4. Blood 2004; 104: 83 [abstract].
30. Andersen OM Benhayon D Curran T Willnow TE. Differential binding of ligands to the apolipoprotein E receptor 2'. Biochemistry 2003; 42: 9355-9364.
31. Pinson KI Brennan J Monkley S Avery BJ Skarnes WC. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 2000; 407: 535-538.
32. 2-glycoprotein I for ApoER2' on platelets is located in domain V. J Biol Chem 2005; 280: 36729-36736.
33. Satta N Dunoyer-Geindre S Reber G. et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007; 109: 1507-1514.
34. Aslam R Speck ER Kim M. et al. Platelet toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006; 107: 637-641.
35. Misch EA Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci 2008; 114: 347-360.
36. Arbour NC Lorenz E Schutte BC. et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-191.
37. Schroder NWJ Schumann RR. Single nucleotide polymorphism of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005; 5: 156-164.
38. Akira S Takeda K. Functions of toll-like receptors: Lessons from KO mice. C R Biol 2004; 327: 581-589.
39. Hoshino K Takeuchi O Kawai T. et al. Cutting edge: Toll-like receptor-4 (TLR-4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR-4 as the LPS gene product. J Immunol 1999; 162: 3749-3752.
40. Cook DN Pisetsky DS Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5: 975-979.
41. Fageras-Bottcher M Hmani-Aifa M Lindstrom A. et al. A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12 (p70) responses in Swedish children. J Allergy Clin Immunol 2004; 114: 561-567.
42. Erridge C Stewart J Poxton IR. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med 2003; 197: 1787-1791.
43. von Aulock S Schroder NW Gueinzius K. et al. Heterozygous Toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 2003; 188: 938-943.
44. van der Graaf C Kullberg BJ Joosten L. et al. Functional consequences of the Asp299Gly Toll-like receptor 4 polymorphism. Cytokine 2005; 30: 264-268.
45. Pierangeli SS Vega-Ostertag ME Raschi E. et al. Toll-like receptor and antiphospholipid mediated thrombosis: In vivo studies. Ann Rheum Dis 2007; 66: 1327-1333.
46. Pasterkamp G van Keulen JK de Kleijn DVP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 2004; 34: 328-334.
47. Fox EA Kahn SR. The relationship between inflammation and venous thrombosis. Tromb Haemost 2005; 94: 362-365.
48. Pierangeli SS Colden-Stanfield M Liu X Barker JH Anderson GH Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 1997-2000.
49. Means TK Jones BW Schromm AB. et al. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol 2001; 166: 4074-4082.
50. Rossignol DP Lynn M. TLR-4 antagonists for endotoxemia and beyond. Curr Opin Investig Drugs 2005; 6: 496-502.
51. Sun S Rao NL Venable J Thurmond R Karlsoon L. TLR7/9 antagonists as therapetics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 2007; 6: 223-235.
52. 2glycoprotein I antibodies. Clin Exp Rheumatol 2007 ; 2: 35 [abstract 147].